Loading…

192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery

BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relative...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2021-11, Vol.9 (Suppl 2), p.A204-A204
Main Authors: Reid, Jack, Zhang, Shihong, Munkhbat, Ariunaa, Ecsedi, Matyas, McAfee, Megan, Chapuis, Aude
Format: Article
Language:English
Subjects:
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A204
container_issue Suppl 2
container_start_page A204
container_title Journal for immunotherapy of cancer
container_volume 9
creator Reid, Jack
Zhang, Shihong
Munkhbat, Ariunaa
Ecsedi, Matyas
McAfee, Megan
Chapuis, Aude
description BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis and screening of individual TCRs based on tetramer binding and peptide specificity, which is costly and labor intensive. We have developed and validated a pooled approach relying on directly cloned TCRs transduced into a fluorescent Jurkat reporter system (figure 1). This approach provides an unbiased, high-throughput method for TCR discovery.MethodsAs a model for POTS, T cells specific for a peptide derived adenovirus structural protein were sorted on tetramer and subjected to 10x single cell VDJ analysis. Pools of randomly paired TCR alpha and beta chains were cloned from the 10x cDNA into a lentiviral vector and transduced into a Jurkat reporter cells. Consecutive stimulations with cognate antigen followed by cell sorts were performed to enrich for functional TCRs. Full length TCRab pools were sequenced by Oxford Nanopore Technologies (ONT) and compared to a 10x dataset to find naturally paired TCRs.ResultsComparison between the ex vivo single cell VDJ sequencing and ONT sequencing of the transduced antigen specific TCRs showed more than 99% of the TCR pairs found in reporter positive Jurkat cells were naturally paired TCRs. The functionality of 8 TCR clonotypes discovered using POTS were compared and clone #2 showed the strongest response. Of the selected clonotypes, clone #2 showed a low frequency of 0.9% in the ex vivo single cell VDJ sequencing. After the first round of stimulation and sequencing, clone #2 takes up of 5% of all reporter-positive clones. The abundance of clone #2 further increased to 17% after another round of stimulation, sorting and sequencing, suggesting this method can retrieve and enrich for highly functional antigen specific TCRs.Abstract 192 Figure 1Outline of the POTS workflow.ConclusionsPOTS provides a high-throughput method for discovery of naturally paired, high-avidity T cell receptors. This method mitigates bias introduced by T cell differentiation state by screening TCRs in a clonal reporter system. Additionally, POTS allows for screening of low abundance clones when compared with traditional TCR discovery techniques. Pooled TCRs could also be screened in vivo with primary T cells in a
doi_str_mv 10.1136/jitc-2021-SITC2021.192
format article
fullrecord <record><control><sourceid>proquest_9YT</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_71557fd840694119bc0c6ca7711bec75</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_71557fd840694119bc0c6ca7711bec75</doaj_id><sourcerecordid>2595870566</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1852-41eba7e8455f13c82a4eb80501499b2ea3ed1c01816d9f434943fe9b12746b193</originalsourceid><addsrcrecordid>eNpFkdtq3DAQhk0h0JDkFYqgNw3UqUYHW7oMSw4LgYTGvRY6jNcy3tVWtgO5y01ftE8Sb7elVxrENz8z8xXFJ6BXALz61sfJl4wyKJ_XzepQXIFmH4pTRiWUIFj1sbgYx55SCpRzpdRpERfi99uvp5QGDKQhHoeBZPS4n1Imo8-Iu7jbkC9Pj83zJdnn9BIDjmTeuWhHDF9JFzddOXU5zZtuP09ki1OXAmmX9mb1nYQ4-vSC-fW8OGntMOLF3_es-HF706zuy4fHu_Xq-qF0oCQrBaCzNSohZQvcK2YFOkUlBaG1Y2g5BvAUFFRBt4ILLXiL2gGrReVA87NifcwNyfZmn-PW5leTbDR_PlLeGJun6Ac0NUhZt0EJWmkBoJ2nvvK2rgEc-louWZ-PWcveP2ccJ9OnOe-W8Q2TWqqayqpaKHak3Lb_DwA1ByvmYMUcZJh_Vsxyc_4O6GKB7g</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2595870566</pqid></control><display><type>article</type><title>192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery</title><source>BMJ Open Access Journals</source><creator>Reid, Jack ; Zhang, Shihong ; Munkhbat, Ariunaa ; Ecsedi, Matyas ; McAfee, Megan ; Chapuis, Aude</creator><creatorcontrib>Reid, Jack ; Zhang, Shihong ; Munkhbat, Ariunaa ; Ecsedi, Matyas ; McAfee, Megan ; Chapuis, Aude</creatorcontrib><description>BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis and screening of individual TCRs based on tetramer binding and peptide specificity, which is costly and labor intensive. We have developed and validated a pooled approach relying on directly cloned TCRs transduced into a fluorescent Jurkat reporter system (figure 1). This approach provides an unbiased, high-throughput method for TCR discovery.MethodsAs a model for POTS, T cells specific for a peptide derived adenovirus structural protein were sorted on tetramer and subjected to 10x single cell VDJ analysis. Pools of randomly paired TCR alpha and beta chains were cloned from the 10x cDNA into a lentiviral vector and transduced into a Jurkat reporter cells. Consecutive stimulations with cognate antigen followed by cell sorts were performed to enrich for functional TCRs. Full length TCRab pools were sequenced by Oxford Nanopore Technologies (ONT) and compared to a 10x dataset to find naturally paired TCRs.ResultsComparison between the ex vivo single cell VDJ sequencing and ONT sequencing of the transduced antigen specific TCRs showed more than 99% of the TCR pairs found in reporter positive Jurkat cells were naturally paired TCRs. The functionality of 8 TCR clonotypes discovered using POTS were compared and clone #2 showed the strongest response. Of the selected clonotypes, clone #2 showed a low frequency of 0.9% in the ex vivo single cell VDJ sequencing. After the first round of stimulation and sequencing, clone #2 takes up of 5% of all reporter-positive clones. The abundance of clone #2 further increased to 17% after another round of stimulation, sorting and sequencing, suggesting this method can retrieve and enrich for highly functional antigen specific TCRs.Abstract 192 Figure 1Outline of the POTS workflow.ConclusionsPOTS provides a high-throughput method for discovery of naturally paired, high-avidity T cell receptors. This method mitigates bias introduced by T cell differentiation state by screening TCRs in a clonal reporter system. Additionally, POTS allows for screening of low abundance clones when compared with traditional TCR discovery techniques. Pooled TCRs could also be screened in vivo with primary T cells in a mouse model to screen for the most functional and physiologically fit TCR for cancer treatment.</description><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1136/jitc-2021-SITC2021.192</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Antigens ; Immunotherapy ; Lymphocytes ; Peptides ; Regular and Young Investigator Award Abstracts ; T cell receptors</subject><ispartof>Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A204-A204</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2595870566/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2595870566?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,55350,75126,77660,77686</link.rule.ids><linktorsrc>$$Uhttps://jitc.bmj.com/content/9/Suppl_2/A204.full$$EView_record_in_BMJ_Publishing_Group_Ltd$$FView_record_in_$$GBMJ_Publishing_Group_Ltd</linktorsrc></links><search><creatorcontrib>Reid, Jack</creatorcontrib><creatorcontrib>Zhang, Shihong</creatorcontrib><creatorcontrib>Munkhbat, Ariunaa</creatorcontrib><creatorcontrib>Ecsedi, Matyas</creatorcontrib><creatorcontrib>McAfee, Megan</creatorcontrib><creatorcontrib>Chapuis, Aude</creatorcontrib><title>192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery</title><title>Journal for immunotherapy of cancer</title><addtitle>J Immunother Cancer</addtitle><description>BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis and screening of individual TCRs based on tetramer binding and peptide specificity, which is costly and labor intensive. We have developed and validated a pooled approach relying on directly cloned TCRs transduced into a fluorescent Jurkat reporter system (figure 1). This approach provides an unbiased, high-throughput method for TCR discovery.MethodsAs a model for POTS, T cells specific for a peptide derived adenovirus structural protein were sorted on tetramer and subjected to 10x single cell VDJ analysis. Pools of randomly paired TCR alpha and beta chains were cloned from the 10x cDNA into a lentiviral vector and transduced into a Jurkat reporter cells. Consecutive stimulations with cognate antigen followed by cell sorts were performed to enrich for functional TCRs. Full length TCRab pools were sequenced by Oxford Nanopore Technologies (ONT) and compared to a 10x dataset to find naturally paired TCRs.ResultsComparison between the ex vivo single cell VDJ sequencing and ONT sequencing of the transduced antigen specific TCRs showed more than 99% of the TCR pairs found in reporter positive Jurkat cells were naturally paired TCRs. The functionality of 8 TCR clonotypes discovered using POTS were compared and clone #2 showed the strongest response. Of the selected clonotypes, clone #2 showed a low frequency of 0.9% in the ex vivo single cell VDJ sequencing. After the first round of stimulation and sequencing, clone #2 takes up of 5% of all reporter-positive clones. The abundance of clone #2 further increased to 17% after another round of stimulation, sorting and sequencing, suggesting this method can retrieve and enrich for highly functional antigen specific TCRs.Abstract 192 Figure 1Outline of the POTS workflow.ConclusionsPOTS provides a high-throughput method for discovery of naturally paired, high-avidity T cell receptors. This method mitigates bias introduced by T cell differentiation state by screening TCRs in a clonal reporter system. Additionally, POTS allows for screening of low abundance clones when compared with traditional TCR discovery techniques. Pooled TCRs could also be screened in vivo with primary T cells in a mouse model to screen for the most functional and physiologically fit TCR for cancer treatment.</description><subject>Antigens</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Peptides</subject><subject>Regular and Young Investigator Award Abstracts</subject><subject>T cell receptors</subject><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpFkdtq3DAQhk0h0JDkFYqgNw3UqUYHW7oMSw4LgYTGvRY6jNcy3tVWtgO5y01ftE8Sb7elVxrENz8z8xXFJ6BXALz61sfJl4wyKJ_XzepQXIFmH4pTRiWUIFj1sbgYx55SCpRzpdRpERfi99uvp5QGDKQhHoeBZPS4n1Imo8-Iu7jbkC9Pj83zJdnn9BIDjmTeuWhHDF9JFzddOXU5zZtuP09ki1OXAmmX9mb1nYQ4-vSC-fW8OGntMOLF3_es-HF706zuy4fHu_Xq-qF0oCQrBaCzNSohZQvcK2YFOkUlBaG1Y2g5BvAUFFRBt4ILLXiL2gGrReVA87NifcwNyfZmn-PW5leTbDR_PlLeGJun6Ac0NUhZt0EJWmkBoJ2nvvK2rgEc-louWZ-PWcveP2ccJ9OnOe-W8Q2TWqqayqpaKHak3Lb_DwA1ByvmYMUcZJh_Vsxyc_4O6GKB7g</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Reid, Jack</creator><creator>Zhang, Shihong</creator><creator>Munkhbat, Ariunaa</creator><creator>Ecsedi, Matyas</creator><creator>McAfee, Megan</creator><creator>Chapuis, Aude</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope></search><sort><creationdate>20211101</creationdate><title>192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery</title><author>Reid, Jack ; Zhang, Shihong ; Munkhbat, Ariunaa ; Ecsedi, Matyas ; McAfee, Megan ; Chapuis, Aude</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1852-41eba7e8455f13c82a4eb80501499b2ea3ed1c01816d9f434943fe9b12746b193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Peptides</topic><topic>Regular and Young Investigator Award Abstracts</topic><topic>T cell receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reid, Jack</creatorcontrib><creatorcontrib>Zhang, Shihong</creatorcontrib><creatorcontrib>Munkhbat, Ariunaa</creatorcontrib><creatorcontrib>Ecsedi, Matyas</creatorcontrib><creatorcontrib>McAfee, Megan</creatorcontrib><creatorcontrib>Chapuis, Aude</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Reid, Jack</au><au>Zhang, Shihong</au><au>Munkhbat, Ariunaa</au><au>Ecsedi, Matyas</au><au>McAfee, Megan</au><au>Chapuis, Aude</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><stitle>J Immunother Cancer</stitle><date>2021-11-01</date><risdate>2021</risdate><volume>9</volume><issue>Suppl 2</issue><spage>A204</spage><epage>A204</epage><pages>A204-A204</pages><eissn>2051-1426</eissn><abstract>BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis and screening of individual TCRs based on tetramer binding and peptide specificity, which is costly and labor intensive. We have developed and validated a pooled approach relying on directly cloned TCRs transduced into a fluorescent Jurkat reporter system (figure 1). This approach provides an unbiased, high-throughput method for TCR discovery.MethodsAs a model for POTS, T cells specific for a peptide derived adenovirus structural protein were sorted on tetramer and subjected to 10x single cell VDJ analysis. Pools of randomly paired TCR alpha and beta chains were cloned from the 10x cDNA into a lentiviral vector and transduced into a Jurkat reporter cells. Consecutive stimulations with cognate antigen followed by cell sorts were performed to enrich for functional TCRs. Full length TCRab pools were sequenced by Oxford Nanopore Technologies (ONT) and compared to a 10x dataset to find naturally paired TCRs.ResultsComparison between the ex vivo single cell VDJ sequencing and ONT sequencing of the transduced antigen specific TCRs showed more than 99% of the TCR pairs found in reporter positive Jurkat cells were naturally paired TCRs. The functionality of 8 TCR clonotypes discovered using POTS were compared and clone #2 showed the strongest response. Of the selected clonotypes, clone #2 showed a low frequency of 0.9% in the ex vivo single cell VDJ sequencing. After the first round of stimulation and sequencing, clone #2 takes up of 5% of all reporter-positive clones. The abundance of clone #2 further increased to 17% after another round of stimulation, sorting and sequencing, suggesting this method can retrieve and enrich for highly functional antigen specific TCRs.Abstract 192 Figure 1Outline of the POTS workflow.ConclusionsPOTS provides a high-throughput method for discovery of naturally paired, high-avidity T cell receptors. This method mitigates bias introduced by T cell differentiation state by screening TCRs in a clonal reporter system. Additionally, POTS allows for screening of low abundance clones when compared with traditional TCR discovery techniques. Pooled TCRs could also be screened in vivo with primary T cells in a mouse model to screen for the most functional and physiologically fit TCR for cancer treatment.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><doi>10.1136/jitc-2021-SITC2021.192</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier EISSN: 2051-1426
ispartof Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A204-A204
issn 2051-1426
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_71557fd840694119bc0c6ca7711bec75
source BMJ Open Access Journals
subjects Antigens
Immunotherapy
Lymphocytes
Peptides
Regular and Young Investigator Award Abstracts
T cell receptors
title 192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A59%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_9YT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=192%E2%80%85Pooled%20T%20cell%20receptor%20screening%20(POTS)%20provides%20unbiased,%20high-throughput%20method%20for%20TCR%20discovery&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Reid,%20Jack&rft.date=2021-11-01&rft.volume=9&rft.issue=Suppl%202&rft.spage=A204&rft.epage=A204&rft.pages=A204-A204&rft.eissn=2051-1426&rft_id=info:doi/10.1136/jitc-2021-SITC2021.192&rft_dat=%3Cproquest_9YT%3E2595870566%3C/proquest_9YT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1852-41eba7e8455f13c82a4eb80501499b2ea3ed1c01816d9f434943fe9b12746b193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2595870566&rft_id=info:pmid/&rfr_iscdi=true